



11<sup>th</sup> February, 2018

✓ The Dy. General Manager (Listing Dept.)  
BSE Limited  
Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
(BSE Scrip Code: 500420)

✓ The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051  
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

**Sub.: Investors Presentation**

Please find attached herewith the updated Investors' presentation for your ready reference. The presentation is also being uploaded on the website of the Company.

Kindly take note of the above.

Thanking you,

Yours Sincerely,  
For TORRENT PHARMACEUTICALS LIMITED

A handwritten signature in black ink, appearing to be 'MAHESH AGRAWAL'.

MAHESH AGRAWAL  
VP (LEGAL) & COMPANY SECRETARY

Encl: As above

**TORRENT PHARMACEUTICALS LIMITED**

CIN : L24230GJ1972PLC002126

Reg.Office : Torrent House, Off Ashram Road, Ahmedabad - 380 009, India. Phone: +91 79 26599000, Fax : +91 79 26582100, [www.torrentpharma.com](http://www.torrentpharma.com)



# Presentation

February 2018



# Disclaimer

The information contained in this presentation is provided by Torrent Pharmaceuticals Limited (the “Company”) to you solely for your reference. This document is being given solely for your information and for your use and may not be retained by you and neither this presentation nor any part thereof may be (i) used or relied upon by any other party or for any other purpose; (ii) copied, photocopied, duplicated or otherwise reproduced in any form or by any means; or (iii) redistributed, passed on or otherwise disseminated, to any other person without the prior written consent of the Company. Although care has been taken to ensure that the information in this presentation is accurate, and that the opinions expressed are fair and reasonable, the information is subject to change without notice, its accuracy is not guaranteed and has not been independently verified. No representation, warranty, guarantee or undertaking (express or implied) is made as to, and no reliance should be placed on, the accuracy, completeness or correctness of any information, including any projections, estimates, targets and opinions, contained herein, and accordingly, none of the Company, its advisors, representatives or any of its directors assumes any responsibility or liability for, the accuracy or completeness of, or any errors or omissions in, any information or opinions contained herein. None of the Company, its advisors, representatives and its directors, officers, employees or affiliates nor any other person accepts any liability (in negligence, or otherwise) whatsoever for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection therewith.

The statements contained in this document speak only as at the date as of which they are made, and the Company expressly disclaims any obligation or undertaking to supplement, amend or disseminate any updates or revisions to any statements contained herein to reflect any change in events, conditions or circumstances on which any such statements are based. By preparing this presentation, none of the Company, its management, and their respective advisers undertakes any obligation to provide the recipient with access to any additional information or to update this presentation or any additional information or to correct any inaccuracies in any such information which may become apparent. This document does not constitute or form part of and should not be construed as an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company or its subsidiary or affiliates in any jurisdiction or as an inducement to enter into investment activity. No part of this document, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. You acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company. This document is not financial, legal, tax or other product advice.



## Disclaimer (cont'd.)

This presentation contains statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers and information currently available with them including with respect to the consolidated results of operations and financial condition, and future events and plans of the Company. These statements can be recognised by the use of words such as “expects”, “plans”, “will”, “estimates”, “intends” or words of similar meaning. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors and assumptions. You are cautioned not to place undue reliance on these forward looking statements, which are based on the current view of the management of the Company on future events. No assurance can be given that future events will occur, or that assumptions are correct. Neither the Company nor its advisors or representatives assume any responsibility to amend, modify or revise any forward-looking statements, on the basis of any subsequent developments, information or events, or otherwise.

This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete. Neither the Company nor any of its advisors or representatives have independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. All industry data and projections contained in this presentation are based on data obtained from the sources cited and involve significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentation for any purpose.

The distribution of these materials in certain jurisdictions may be restricted by law and persons into whose possession these materials comes should inform themselves about and observe any such restrictions.

This presentation and the information contained herein does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. This presentation is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration.

By accessing this presentation, you accept that this disclaimer and any claims arising out of the use of the information from this presentation shall be governed by the laws of India and only the courts in India, and no other courts, shall have jurisdiction over the same.



# Torrent Pharma at a Glance

## One of the leading pharma companies in India with a global presence

- Incorporated in 1971, with its headquarters in Ahmedabad, India
- 8<sup>th</sup> largest Pharma company in India<sup>4</sup>
- 15,000+ employees
- Amongst the leaders in Cardiovascular, CNS, VMN and GI therapeutic segments in IPM<sup>3</sup>
- 18 brands in the Top 500 IPM brands<sup>4</sup>

## Presence across key Pharma Markets

- Developed markets like USA, Germany & UK
- High-growth emerging markets such as India, Brazil & Mexico
- Operates through 25+ sales and marketing divisions in India, structured on key therapeutic areas- with a field force of 6,500+


## Vertical integration assuring quality & supply

- Developing and Manufacturing APIs and Formulations
- Product development for multiple dosage forms
- In-house BE studies
- Facilities are approved by key developed market regulators like USFDA, WHO, MHRA, TGA & other global regulatory bodies


## Track record of value creation from acquisitions

- Unichem Labs' Branded business in India & Nepal, with over 120 brands
- Elder Pharma's domestic formulations business with 30 brands

## Revenue split by geographical segment



## Revenue<sup>1</sup> (INRcr) and EBITDA margin<sup>2</sup> %




Source: AIOCD; Note: Financial data in the presentation is derived from the financial statements of the company prepared under Ind AS for FY17 and 9M18 and Indian GAAP for FY15 and FY16; <sup>1</sup> Revenue from operations (net)

<sup>2</sup> EBITDA = Profit before tax and exception items + Finance costs + Depreciation, amortisation and impairment expense – Interest income and EBITDA margin = EBITDA / total revenue; <sup>3</sup> Exceptional revenue/ gain in FY16 on account of limited competition in one molecule in US; <sup>4</sup> For MAT Dec'17 as per AIOCD




# Torrent Pharmaceuticals: The journey so far...

Track-record of successful acquisitions: Well thought strategic acquisitions to deepen focused therapies and expand to lucrative geographies




# Track-record of shareholder value creation


## Revenue (INRcr)




## EBITDA<sup>1</sup> (INRcr): Phenomenal margin expansion



## Net income (INRcr)



## Market cap. (INRcr)



Source: Company filings, NSE

Note: Financial data in the presentation is derived from the financial statements of the company prepared under Ind AS for FY17 and 9M18 and Indian GAAP for all prior years

<sup>1</sup> EBITDA = Profit before tax and exception items + Finance costs + Depreciation, amortisation and impairment expense – Interest income and EBITDA margin = EBITDA / total revenue



## Key highlights

- 1 Strong position in India
- 2 Proven ability to build market leading brands
- 3 Track-record of successful integration of acquisitions
- 4 Balance mix with well entrenched position in developed and emerging markets
- 5 Strategic advantage via vertical integration with in-house API and formulations manufacturing capabilities
- 6 Strong research and development capabilities
- 7 Experienced founders and professional management team with strong track-record






# 1 Strong position in India ...

## Market leadership


- #8 company in domestic formulations market
- Domestic market share of 3.2% with a sizeable MAT of INR3,710cr (Dec'17)
- Increasing exposure to the India market through Elder and Unichem acquisition

## MAT growth (Dec'15-Dec'17)



## Strong positioning in micro-markets



### Leadership therapeutic areas



Source: AIOCD  
Note: <sup>1</sup> Excludes Unichem contribution


## Majority contribution from high growth chronic business

- Continued focus on chronic business
  - Comparatively higher growth
  - More sustainable
  - Higher stickiness
- Highest exposure to chronic segment among all the top 10 companies in India
- Torrent chronic and sub-chronic share of 77% v/s IPM of 52%



MAT Dec'17 value: INR2,727cr<sup>1</sup>

### Emerging therapeutic areas



# 1 ... with an extensive sales and distribution network

## Extensive sales, marketing and distribution network in India



23  
C&F




5,000+  
Stockists




6,500+  
Field force

## Strategic business units for focused sales



- Wide distribution reach across India through 5,000+ stockists
- Focus on business hygiene for improved business predictability
- Sustained brand building approach
- Specialty driven business model with focus on improving productivity
- One of the leading player in IPM amongst specialties- Cardiologist, diabetologist, psychiatrist, gastro, nephro & neuro



## Transformation driving productivity


2012-13	2013-14	2014-15	2015-16	2016-17	2017-18
<ul style="list-style-type: none"> <li>■ Identifying areas for process improvements</li> </ul>	<ul style="list-style-type: none"> <li>■ Portfolio re-alignment</li> <li>■ Specialty approach</li> <li>■ Business development initiatives</li> </ul>	<ul style="list-style-type: none"> <li>■ Team stability</li> <li>■ Field force rationalization</li> <li>■ NI pipeline</li> <li>■ Acquisition of Elder</li> </ul>	<ul style="list-style-type: none"> <li>■ Business Hygiene</li> <li>■ Continuing specialty approach</li> <li>■ Entry into MABs</li> </ul>	<ul style="list-style-type: none"> <li>■ Focus on Rx generation</li> <li>■ Enhancing productivity from specialties</li> </ul>	<ul style="list-style-type: none"> <li>■ Acquisition of Unichem</li> </ul>




## 2 Proven ability to build market leading brands - *Reputable brands across the therapeutic areas*

- ✓ Strong ability to build reputable brands
- ✓ 18 brands among top 500 brands
- ✓ 15 brands over INR50cr including 7 brands over INR100cr

### Leading brands



### Leading brands acquired as part of Unichem transaction



Source: AIOCD MAT Dec 17




### 3 Track-record of successful integration of acquisitions

- ✓ Track record of successfully closing and integrating acquisitions into existing business
- ✓ Acquired business with large field-force successfully absorbed
- ✓ Acquisitions driven by long term strategic intent and turnaround strategy which demonstrates right capital allocation

**December 2013**

**Acquired brands from Elder**




- Acquired domestic formulation business consisting 30 brands from Elder including women's healthcare, pain management, wound-care and nutraceuticals in FY14-15
- Top brands included Shelcal and Chymoral

**May 2017**

**Acquired brands from Novartis**

**Regestrone**

Y-o-Y growth for each quarter



- Turnaround of sales of Regestrone since acquisition

**November 2017**

**Acquired branded business of Unichem in India and Nepal**

- Unichem:
  - 120 brands and manufacturing plant at Sikkim
  - Strengthening presence in Cardiology, Diabetology, GI and CNS

**January 2018**

**Acquired Bio-Pharm**

Source: AIOCD MAT Dec'17, Newsrun




Overview

FY17  
Revenue  
Contribution<sup>1</sup>  
(INRcr)


### India

- 8<sup>th</sup> largest player in the Indian Pharma Market with a market share of 3.4% (Post Unichem acquisition)
- Strong Portfolio of brands with leading position in key therapeutic areas (2<sup>nd</sup> in Cardiology, 4<sup>th</sup> in Neuro and VMN respectively, 6<sup>th</sup> in Gastrointestinal)
- Strong focus on Chronic & sub-chronic segments




### US

- The company has built a healthy pipeline of 93 filed ANDAs of which 29 ANDAs are pending for final approvals
- Launched limited competition products: gAbilify and gCymbalta




### Brazil

- Largest Indian pharma company in Brazil
- Torrent ranked 15<sup>th</sup> amongst all pharma companies (Rx ranking)
- 37 molecules with 11 major brands



### Germany

- **Germany**
  - 4<sup>th</sup> largest generic company in the retail segment
  - 120+ molecules encompassing oral solids, patches, liquids, opioids, oncology products
  - OTC contributes to 10% of the business



Source: Close-up dataset, AIOCD, Insight health – NVI – KTPLUS

Note: Financial data in the presentation is derived from the financial statements of the company prepared under Ind AS for FY17

<sup>1</sup> Denotes % contribution to revenues from external customers which also includes revenue from other countries, CRAM and other revenues




## 4 Balance mix with well entrenched position in developed and emerging markets - *Focused US market approach:* *Targeting niche opportunities and well thought molecule expansion strategy*

### Overview


- Exceptional gain in FY16 on account of limited competition in Aripiprazole in the US
- Pipeline includes products like ointments and specialty oral solids (oncology) including external collaborators for the development of products for the US market
- Total products under development: 77

### Revenue evolution (INRcr)




### Increasing products in the top 3 of respective segment

# products



### ANDA overview



Source: IMS

Note: Financial data in the presentation is derived from the financial statements of the company prepared under Ind AS for FY17 and 9M18 and Indian GAAP for FY15 and FY16



### Overview


#### ■ Germany:

- 4<sup>th</sup> largest pharma company despite entry in 2005 through acquisition of Heumann Pharma
- Several new product launches each year in the last 3 years
- Focus on products with low volumes and high value

#### ■ UK

- Acquired portfolio of products from Cipla /Actavis in 2014
- 34 molecules are marketed in the country, with 108 licenses
- Licensing business
  - Follows a licensing model in many of the European countries
  - More than 40 products registered with 35+ partners across Europe

### Germany revenue evolution (INRcr)



Source: Insight health – NVI – KTPLUS

Note: Financial data in the presentation is derived from the financial statements of the company prepared under Ind AS for FY17 and 9M18 and Indian GAAP for FY15 and FY16




## 4 Balance mix with well entrenched position in developed and emerging markets - *Brazil*


### Overview

- Ranks #1 in terms of market share, among Indian Companies
- 7 brands over INR50cr including 3 brands over INR100cr

### PCPM overview ('000s)



### Brazil revenue evolution (INRcr)



### Evolution of Brazil Business

2013-14	2015-16	2016-17	2017-18 1H
<ul style="list-style-type: none"><li>■ Nebivolol launch</li><li>■ Competitive Pricing Strategy for key brands</li></ul>	<ul style="list-style-type: none"><li>■ Brand Building Focus</li><li>■ TA Based Divisions</li><li>■ Field Force Rationalization</li><li>■ Pipeline Development</li></ul>	<ul style="list-style-type: none"><li>■ Defocus on Govt. Business</li><li>■ Launch of Olmecor and Trazodone</li></ul>	<ul style="list-style-type: none"><li>■ Implementation of Controls and SOPs for Sales' Channel Management</li></ul>


Source: Close-up dataset

Note: Financial data in the presentation is derived from the financial statements of the company prepared under Ind AS for FY17 and 9M18 and Indian GAAP for FY15 and FY16





5 Strategic advantage via vertical integration with in-house API and formulations manufacturing capabilities



Also operates a US based facility acquired as part of the Bio-Pharm acquisition in January 2018

Only domestic pharma company among top 10 to not have received any warning by USFDA, exhibiting superior technical capabilities



## 5 FDA Inspection track record since 2006

Site	Inspection End date	Status
Indrad	April, 2006	Significant 483, Resolved
	April, 2008	Insignificant 483, Resolved
	Mar, 2011	No 483, Compliant
	July, 2013	No 483, Compliant
	Mar, 2015	Insignificant 483, Resolved
	May, 2016	Insignificant 483, Resolved
	Apr, 2017	Insignificant 483, Resolved
Dahej	Apr, 2015	Insignificant 483, Resolved
	Jun, 2017	Insignificant 483, Resolved
Indore	Sep, 2011	Insignificant 483, Resolved
	May, 2014	Insignificant 483, Resolved
	Apr 2016	Insignificant 483, Resolved
Vizag	Apr 2009	Insignificant 483, Resolved
	Jan 2013	Insignificant 483, Resolved
	Dec 2015	Insignificant 483, Resolved
BE Centre	Sep, 2009	Insignificant 483, Resolved
	Mar, 2013	Insignificant 483, Resolved
	Mar, 2015	Insignificant 483, Resolved
US-Office (PV activity)	Aug, 2011	No 483, Compliant
	Dec, 2014	No 483, Compliant




## 6 Strong research and development capabilities

### KEY R&D capabilities

Infrastructure	<ul style="list-style-type: none"><li>▪ Built-up Area - 441,000 sq. ft.<ul style="list-style-type: none"><li>— Laboratories - 280,000 sq. ft.</li><li>— Support Services - 161,000 sq. ft.</li></ul></li><li>▪ 56 bedded hospital</li><li>▪ Approved by: US-FDA, ANVISA (Brazil), EU-AFFSAPS (France)</li></ul>
Scientists	<ul style="list-style-type: none"><li>▪ 900+</li></ul>

### Significant investment in R&D (INRcr)



Note: Financial data in the presentation is derived from the financial statements of the company prepared under Ind AS for FY17 and 9M18 and Indian GAAP for FY15 and FY16

### Focus areas

#### Complex Generics

- Oral (Sprinkles, Retard, Compact, Osmotic)
- Oncology
- Derma
- Ophthalmology
- Injectables

#### Value Added Generics

- NDDS, 505 B(2)
- Therapeutic areas: Dermatology, CNS – pain, VMS, Women’s Health
- L.A. Injectable, Foams, Nasal Sprays

#### Discovery

- NCEs for emerging markets
- Two advanced projects in phase III



# Strategy



# Key strategies

<b>Increase market share in India</b>	<ul style="list-style-type: none"><li>■ Maintain market leadership in specialist segments</li><li>■ Continue to build large brands in our core therapeutic areas</li><li>■ Focus on field force productivity</li></ul>
<b>Pursue inorganic strategic opportunities</b>	<ul style="list-style-type: none"><li>■ Pursue inorganic growth opportunities to gain access to platforms with capabilities, product portfolio and established brands which are complimentary</li><li>■ Focus on successful integration of acquired entities to generate significant synergies and create value for shareholders</li></ul>
<b>Expansion in developed geographies such as US, UK and Europe</b>	<ul style="list-style-type: none"><li>■ Continue to focus on the existing and new generic products and enhance product portfolio by accelerating ANDA filings in diversified dosage forms</li><li>■ Identify new potential opportunities in the generics space</li></ul>
<b>Focus on research and development to enhance our product portfolio</b>	<ul style="list-style-type: none"><li>■ Increase our initiatives in research and development in order to enhance our differentiated product portfolio in both the domestic market and international markets and to enhance ANDA filings in the United States</li><li>■ Continue to focus on formulation development and API research</li><li>■ Develop capabilities and expertise in niche areas with high entry barriers</li></ul>
<b>Pursue growth in emerging markets</b>	<ul style="list-style-type: none"><li>■ Consolidate market share in the existing geographies</li><li>■ Achieve growth by leveraging existing relationships with customers and expanding product portfolio with a focus on branded generic formulations in our leading therapeutic areas</li></ul>




# Financials




# Financials

(All figures in INRcr)


## Total Revenue




## EBITDA<sup>1</sup> & EBITDA Margin<sup>2</sup>




## PAT




## Cash & Cash Equivalent<sup>3</sup>



## Net Debt<sup>4</sup>



## Total Assets



Note: Financial data in the presentation is derived from the financial statements of the company prepared under Ind AS for FY17 and 9M18 and Indian GAAP for FY15 and FY16

<sup>1</sup> EBITDA = Profit before tax and exception items + Finance costs + Depreciation, amortisation and impairment expense – Interest income; <sup>2</sup> EBITDA margin = EBITDA / total revenue

<sup>3</sup> Cash and Cash equivalents = Cash and Cash Equivalents + Current Investments + Bank deposits other than cash and cash equivalents

<sup>4</sup> Net Debt = Long-term borrowings + Short-term borrowings + Current maturity of Long term borrowing – (Cash and Cash Equivalents + Current Investments + Bank deposits other than cash and cash equivalents)



**Thank You**

